A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Clinical trial NCT01744691 · COMPLETED

Trial details

NCT number: NCT01744691
Sponsor: Pharmacyclics LLC.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia With 17p Deletion Small Lymphocytic Lymphoma With 17p Deletion

Start date: 2013-01-01
Primary completion: 2014-06-01
Enrollment: 145

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.